GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic ...

Delhi High Court bars Dr Reddy's and OneSource from selling semaglutide in India, supporting Novo Nordisk's patent rights as ...

The court’s intervention comes at a crucial time as Novo Nordisk gears up for the rollout of Wegovy, amid rising global ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

The research will focus on the use of GLP-1 receptor agonist medications and their possible cognitive benefits in aging ...

In patients with T2D, GLP-1s don’t increase the risk for acute pancreatitis, mitigate the risk for complications in those who develop it, and reduce the risk for all-cause mortality.

PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of ...

In a head-to-head diet-induced obese (DIO) mouse model, low dose ASC47 in combination with semaglutide demonstrated a 56.7% greater reduction in body weight with muscle preservation compared to ...

In light of controversy over the recent semaglutide drug shortages for the diabetes patients they're indicated for, one doctor illuminates another side of the case. From the Kardashians to that person ...